Fox Chase Cancer Center Presentations at the ASCO Annual Meeting

PHILADELPHIA (May 24, 2018) – As nearly 40,000 cancer researchers, physicians, and advocates gather in Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting, over 20 Fox Chase Cancer Center faculty and students will present their research on a range of topics. These presentations will take place at various times and locations throughout the five- day event.

Friday, June 1 

Hossein Borghaei, DO, MS 
3:25 – 3:34 PM 
Education Session 
Novel immunotherapy combinations in the initial management of non-small cell lung cancer 
Hall D1

Saturday, June 2 

Margaret von Mehren, MD 
8:00 – 11:30 AM 
Poster Session 
A retrospective natural history study of patients with PDGFRa D842V mutant advanced gastrointestinal stromal tumor previously treated with a tyrosine kinase inhibitor. 
Hall A

Michael J. Hall, MD, MS 
1:15 – 4:45 PM 
Poster Session 
Long-term (7-year) outcomes of universal mismatch repair screening of 1156 colorectal (CRC) and endometrial cancers (EC) in an academic setting. 
Hall A

Michael J. Hall, MD, MS 
1:15 – 4:45 PM 
Poster Session 
Feasibility of perioperative multigene panel testing in cancer patients eligible for hereditary genetic evaluation. The PROTECT pilot. 
Hall A

Chethan Ramamurthy, MD 
1:15 – 4:45 PM 
Poster Session 
Cost-effectiveness analysis of abiraterone acetate versus docetaxel for the management of metastatic hormone naïve prostate cancer. 
Hall A

Sunday, June 3 

Joseph Nicholas Bodor, MD, PhD 
9:24- 9:36 AM 
Oral Abstract Session 
Pathogenic somatic mutation of mismatch repair genes and associations with microsatellite instability, tumor mutational burden and SM in other DNA repair pathways in 24,223 tumor genomic profiles. 
S404

Namrata Vijayvergia, MD 
8:00 – 11:30 AM 
Poster Session 
Pembrolizumab monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms. 
Hall A

Martin Edelman, MD 
8:00 – 11:30 AM 
Poster Session 
A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer. 
Hall A

David Chen, MD 
5:00 – 5:30 PM 
Plenary Session 
Panelist 
S100a

Monday, June 4 

Elizabeth Plimack, MD, MS 
7:45 – 8:00 AM 
Genitourinary Cancer 
Hall D1

Mark N. Stein, MD; Wafik S. El-Deiry, MD, PhD, FACP 
8:00- 11:30 AM 
Poster Session 
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. 
Hall A

Stefan K. Barta, MD, MRCP, MS 
8:00 – 11:30 AM 
Poster Session 
Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non Hodgkin lymphoma, myeolfibrosis, chronic lymphocytic leukemia and solid tumors. 
Hall A

Stefan K. Barta, MD, MRCP, MS 
8:00 – 11:30 AM 
Poster Session 
Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma. 
Hall A

Lainie P. Martin, MD 
1:15 – 4:45 PM 
Poster Session 
Phase 1 study of carboplatin, pegylated liposomal doxorubicin and everolimus in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse. 
Hall A

Kuang-Yi Wen, PhD 
1:15 – 4:45 PM 
Poster Session 
Randomized trial of a text messaging intervention for symptom distress in BCa patients undergoing chemotherapy. 
Hall A

Pooja Ghatalia, MD; Wafik S. El-Deiry, MD, PhD, FACP  
1:15 – 4:45 PM 
Poster Session 
Liquid biopsies across treatment of 29 metastatic colorectal cancer patients to reveal driver mutations and tumor evolution with anti-EGFR therapy: Experience in a GI oncology clinic at Fox Chase Cancer Center. 
Hall A

Razelle Kurzrock, MD; Wafik S. El-Deiry, MD, PhD, FACP  
1:15 – 4:45 PM 
Poster Session 
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq. 
Hall A

Hossein Borghaei, DO, MS 
3:12 – 3:24 PM 
Oral Abstract Session 
Nivolumab + platinum-doublet chemotherapy vs chemo as first-line treatment for advanced non-small cell lung cancer with <1% tumor PD-L1 expression: Results from Checkmate 227. 
Hall B1

Wafik S. El-Deiry, MD, PhD, FACP
5:39 PM – 5:51 PM
Poster Discussion Session
Resources and Tools for Precision Oncology: cfDNA Genome Atlas and PDX Models
S406

Tuesday, June 5 

Wafik S. El-Deiry, MD, PhD, FACP
8:00 AM – 11:00 AM
Chair
Oral Abstract Session; Tumor Biology
S406

Hossein Borghaei, DO, MS 
8:36 – 8:48 AM 
Oral Abstract Session 
Circulating Biomarkers for Immunotherapy: Are They Ready for Your Clinic? 
S406 

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text